Search Results
Sep 18, 2025, 11:57 ET Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransformer® Manufacturing Capabilities
NanoTransformer® platform designed to improve the solubility and bioavailability of poorly water-soluble molecular drugs. NPS develops its own pipeline of CNS medicines while partnering with pharmaceutical companies to enhance delivery of challenging APIs. The NanoTransformer® technology uses a patented physical
More news about: Mikart, LLC
Sep 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
a pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 17, 2025, 11:03 ET Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.
cell-specific promoters, enabling durable rescue of gene expression with minimal off-target effects. Regel's lead programs focus on severe pediatric CNS disorders, including Dravet Syndrome and SCN2A haploinsufficiency. The company is headquartered in Cambridge, MA. For
More news about: Regel Therapeutics Inc.
Sep 17, 2025, 08:30 ET MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
positioned as a potential treatment for ADP based on the favorable safety and tolerability profile observed in healthy elderly volunteers in Phase 1 whose CNS exposures achieved or exceeded levels that we anticipate being clinically relevant," said Erin Foff, M.D., Ph.D., Chief
More news about: MapLight Therapeutics, Inc.
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
miR23b - - Funding to also advance a broader pipeline of targeted RNA medicines across areas of high unmet need in muscular, CNS, cardiac conditions - VALENCIA, Spain,
More news about: ARTHEx Biotech
Sep 16, 2025, 08:00 ET Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
synergistic and durable anti-inflammatory effects. Highlights from Cohort 1: COYA 303 produced significant systemic and CNS immunomodulatory effects in the LPS model of inflammationCOYA 303 significantly (a) enhanced Treg numbers and suppressive function, (b) reduced
More news about: Coya Therapeutics, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers ernennt John Gellatly zum Senior Advisor
YORK, 16. September 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) gab heute die Ernennung von John Gellatly zum Senior Advisor bekannt. Von London aus wird
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers Appoints John Gellatly as Senior Advisor
YORK, Sept. 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of John Gellatly as Senior Advisor. Based in London,
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers benoemt John Gellatly tot senior adviseur
YORK, 16 september 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) kondigde vandaag de benoeming aan van John Gellatly als senior adviseur. Vanuit Londen zal de heer Gellatly nauw samenwerken
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers nomme John Gellatly comme conseiller principal
NEW YORK, 16 septembre 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE : CNS) a annoncé aujourd'hui la nomination de John Gellatly au poste de conseiller principal. Basé à Londres, M. Gellatly travaillera en étroite collaboration
More news about: Cohen & Steers, Inc.
Sep 15, 2025, 16:20 ET Cohen & Steers Announces Chief Financial Officer Transition
YORK, Sept. 15, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Raja Dakkuri, Executive Vice President and Chief Financial Officer, has provided notice of his decision
More news about: Cohen & Steers, Inc.